Nuo Therapeutics, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 13, 2026, reporting financial results for both the three and nine months ended on that date.

Key Highlights

  • Total revenue nearly doubled year over year: Revenue for the three months ended September 30, 2026 was $1,866,125, compared to $1,032,096 in the same period of 2025, according to the filing.
  • Net loss narrowed in Q3: The company reported a net loss of $424,928 for the three months ended September 30, 2026, versus a net loss of $537,919 for the same quarter in 2025.
  • Nine-month revenue grew sharply: Total revenue for the nine months ended September 30, 2026 was $4,937,226, up from $2,216,679 in the same period of 2025.
  • Accumulated deficit increased: The accumulated deficit stood at $36,093,157 as of September 30, 2026, compared to $34,772,162 as of December 31, 2025.
  • Total stockholders' deficit widened: Total stockholders' deficit was $(1,848,504) at September 30, 2026, versus $(956,559) at December 31, 2025.
  • Shares outstanding: As of November 12, 2026, the registrant reported 48,585,593 shares of common stock outstanding at a par value of $0.0001.
  • Cash declined: Cash was $80,941 at September 30, 2026, down from $548,946 at December 31, 2025.

Nuo Therapeutics Reports Q3 2026 Financial Results: Revenue Growth Alongside Wider Deficit

According to the filing, Nuo Therapeutics, Inc. (OTC:AURX) generated total revenue of $1,866,125 for the three months ended September 30, 2026, comprised of $1,779,563 in product sales and $86,562 in distribution fee revenue. This compares to total revenue of $1,032,096 in the third quarter of 2025. Gross profit for the quarter was $1,192,791, up from $625,375 in the prior-year period. Selling, general and administrative expenses were $1,567,223 for the quarter, resulting in a loss from operations of $374,432.

For the nine months ended September 30, 2026, the company disclosed total revenue of $4,937,226, against $2,216,679 for the comparable 2025 period. Product sales accounted for $4,694,782 of that figure, with $242,444 from distribution fee revenue. The nine-month net loss was $1,320,995, compared to $1,933,736 in the first nine months of 2025. Net interest expense for the nine-month period was $340,447, compared to a nominal $33 in the year-ago period, reflecting increased debt activity including warrants issued in connection with notes payable.

The consolidated balance sheet as of September 30, 2026 showed total assets of $2,730,205 and total liabilities of $4,578,709, producing the stockholders' deficit of $(1,848,504). Notes payable totaled $961,875, and notes payable to a related party were $210,500. Accounts receivable, net rose to $1,410,322 from $561,667 at December 31, 2025. During the nine months ended September 30, 2026, the company issued common stock for services and recorded stock-based compensation of $154,255, according to the cash flow statement.

What Was Disclosed

Nuo Therapeutics filed its quarterly report covering the period ended September 30, 2026, disclosing revenue growth, a narrower quarterly net loss compared to Q3 2025, a widening accumulated deficit of $36,093,157, and reduced cash of $80,941 relative to year-end 2025.